However, there are still several limitations in our work: the samples from parents who underwent sorafenib treatment in early stage of HCC were obtained with great difficulty; the patients who had the second hepatectomies were a few, epically after sorafenib therapy failing; the binding sites for protein interactions of CBX4 and YAP1 would be explored or predicted reliably; and the protein modification of YAP1 such as phosphorylation or ubiquitin would be considered. Here, CBX4 is linked to hepatocellular carcinoma.